Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
In STRIDE‑7, the adult‑specific 21‑valent conjugate vaccine V116 produced robust opsonophagocytic responses across all 21 serotypes and had a favorable tolerability profile in adults living with HIV, supporting broader serotype coverage com
The GAME CHANGER randomized trial found cefiderocol non‑inferior to standard‑of‑care antibiotics for 14‑day mortality in hospital‑acquired and healthcare‑associated Gram‑negative bloodstream infection; no superiority was seen, including in
The CloCeBa trial found cefazolin non‑inferior to cloxacillin for meticillin‑susceptible Staphylococcus aureus (MSSA) bacteraemia, with similar 90‑day composite outcomes and substantially lower rates of serious adverse events and acute kidn
A prespecified pooled analysis of two large randomised pragmatic trials (DANFLU-2 and GALFLU) found high‑dose influenza vaccine reduced hospitalisation for influenza or pneumonia by 8.8% versus standard‑dose in adults ≥65 years, with larger
Post hoc analysis of the MELODY Phase 3 trial shows nirsevimab reduced RSV-associated lower respiratory tract infections and RSV coinfections in healthy term and late-preterm infants, with no signal of viral replacement by other respiratory
A nationwide retrospective study from Chile finds that a universal nirsevimab immunisation strategy in 2024 reduced RSV-related lower respiratory tract infection hospitalisations by 76% and ICU admissions by 85%, with an NNT of 35 to preven
A multicentre retrospective TriNetX analysis found reduced odds of RSV test-positivity for infants receiving nirsevimab when last dose was within 6–11 months before testing; protection was strongest within 6 months and not evident beyond 12
Real-world surveillance from 2024–2025 shows substantial reductions in RSV-associated hospitalizations among infants after broad availability of maternal RSV vaccination and nirsevimab, with effectiveness estimates approximating those from
A phase 1 trial of the rVSV‑vectored Lassa vaccine demonstrated dose-dependent transient reactogenicity, no vaccine‑related serious adverse events or hearing loss, and robust, durable humoral and cellular responses across doses and lineages
A large Asian cohort study shows serum HBsAg <100 IU/mL reliably identifies inactive chronic hepatitis B patients whose annual HCC risk is <0.2%, potentially allowing de‑escalation of surveillance and informing partial HBV cure defini
In the phase 2 REEF‑IT trial, pegylated interferon‑α2a added to siRNA JNJ‑73763989 produced large HBsAg reductions and transient seroclearance in some untreated HBeAg‑positive patients, but no participant reached the prespecified sustained
A multinational cohort study of 1,986 patients with indeterminate chronic hepatitis B (CHB) shows large differences in long‑term hepatocellular carcinoma (HCC) risk by baseline indeterminate subtype and by phase transition, identifying subg
National APSU surveillance (1999–2024) found 479 definite congenital CMV cases and dramatic under-ascertainment versus expected prevalence; symptomatic infants increasingly receive antivirals. Expanded surveillance, newborn screening, and c
This study identifies clinical and demographic factors associated with positive blood cultures in hospitalized children across nine African and Asian countries, aiming to improve diagnostic stewardship amidst resource constraints.
This study assesses the feasibility and performance of using self-collected urine and vaginal samples with the BD Onclarity® HPV assay for cervical cancer screening in Japanese women with abnormal cytology, highlighting concordance and sens
The REPAIR study demonstrates that prophylactic antibiotics reduce clinically relevant wound complications after episiotomy or second degree tears, highlighting a potential role for antibiotics in postpartum care.
A booster dose of the hexavalent group B streptococcus conjugate vaccine (GBS6) administered approximately two years after the primary dose in healthy adults is safe and elicits robust, enhanced immune responses, promising for maternal immu
A novel live attenuated oral vaccine, CVD 1902, shows 73% efficacy against Salmonella Paratyphi A infection in a controlled human challenge model, offering promising protection with a favorable safety profile.
A large international trial found that selective decontamination of the digestive tract (SDD) during mechanical ventilation did not reduce hospital mortality but decreased bloodstream infections and antibiotic-resistant organisms, with no c
A pragmatic randomized trial in Kenyan public hospitals demonstrates that adjunctive low-dose glucocorticoid therapy significantly reduces 30-day mortality in adults with community-acquired pneumonia without increasing serious adverse event
Open language-specific specialty feeds and department pages.